China’s Bloomage Biotech Set To Produce Exportable Medical Products
This article was originally published in PharmAsia News
Executive Summary
Bloomage Biotechnology, a new biotech in China, is set to begin producing injectable hyaluronic acid in October and apply for its U.S. FDA approval for medical uses. Bloomage is the sole company licensed in mainland China to sell the chemical for medical use. Hyaluronic acid is considered equivalent to botox and is used primarily in cosmetics, but about 25 percent of Bloomage sales come from products with medical applications. The firm conducted clinical trials of hyaluronic acid products over the past year. (Click here for more